IFNAR2 Antibody

IFNAR2 Antibody Datasheet

IFNAR2 Antibody Product Information

• Immunogen: Recombinant Human IFNAR2 protein (Catalog#10359-H08H)
• Antibody Type: Mouse Monoclonal Antibody ( Mouse mAb Service Platform )
• Clone ID: 8D2B1F1
• Ig Type: Mouse IgG1
• Formulation: 0.2 μm filtered solution in PBS with 5% trehalose
• Preparation: This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IFNAR2 (rh IFNAR2; Catalog#10359-H08H; NP_997468.1; Met 1-Lys 243). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.

IFNAR2 Antibody Usage Guide

• Specificity: Human IFNAR2
• No cross-reactivity in ELISA with

  Human cell lysate (293 cell line)

• Western blot: This antibody can be used at 1-2 μg/mL with the appropriate secondary reagents to detect Human IFNaR2 in WB. Using a DAB detection system, the detection limit for Human IFNaR2 is approximately 4 ng/lane under non-reducing conditions.Use of this antibody under reducing conditions is not recommended.
• Direct ELISA: This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human IFNaR2. The detection limit for Human IFNaR2 is approximately 0.039 ng/well.
• Storage: This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
  Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

IFNAR2 Antibody Background

Interferon alpha/beta receptor 2, also known as IFN-alpha/beta receptor 2, Type I interferon receptor 2, IFNAR2 and IFNABR, is a single-pass type I membrane protein which belongs to thetype II cytokine receptor family. IFNAR2 is a receptor for interferons alpha and beta. IFNAR2 was detected in most lymphocytes, monocytes, and granulocytes, although IFNAR2 expression was higher in the monocytes and granulocytes than in the lymphocytes. The intra- and interdaily variations of IFNAR2 in lymphocytes, monocytes, and granulocytes were small. Among the lymphocyte subsets, IFNAR2 showed high expression in natural killer (NK) cells and low expression in T lymphocytes. Isoform 1 and isoform 3 of IFNAR2 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity. Defects in IFNAR2 are associated with susceptibility to hepatitis B virus infection (HBV infection). Approximately one third of all cases of cirrhosis and half of all cases of hepatocellular carcinoma can be attributed to chronic HBV infection. HBV infection may result in subclinical or asymptomatic infection, acute self-limited hepatitis, or fulminant hepatitis requiring liver transplantation.

References

1. Novick D. et al.,1995, J. Leukoc. Biol. 57: 712-18.
2. Chill JH. et al., 2003, Structure 11: 791-802.
3. Tochizawa,S. et al.,2004, J Pharmacol Toxicol Methods. 50 (1): 59-66.
4. Frodsham A.J. et al., 2006, Proc. Natl. Acad. Sci. USA. 103: 9148-53.